|What is it?||Lemtrada is a humanized monoclonal antibody directed at CD52 (a protein on the surface of immune cells) and it causes depletion of lymphocytes (white blood cells)|
|What does it do?||Alemtuzumab is used to treat relapsing forms of multiple sclerosis.medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). In patients with relapsing forms of multiple sclerosis, natalizumab has been shown to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations.|
|How does it work?||Lemtrada works by binding to and killing immune cells (lymphocytes or white blood cells) which are involved when the immune system attacks myelin. It is thought that the cells which grow back after treatment do not cause damage to nerves|
|How is it taken?||Alemtuzumab is injected into a vein through an IV. A healthcare provider will give you this injection, which can take up to 4 hours to complete.|
|Clinical Results and FDA approval||The FDA approved Lemtrada in November 2014, based on the results of two large, phase III clinical trials that confirmed its ability to significantly reduce relapse rates over two years over standard subcutaneous dosing of Rebif® (interferon beta-1a, EMD Serono Inc. and Pfizer). One of the studies also suggested that Lemtrada may significantly reduce worsening of disability.
Clinical Trial One
Clinical Trial Two
|What are the side effects ?||Patient Guide